GLPGF News and Press, Galapagos Genomics Ord From 05/05/23

2023-05-05 12:47:05 ET Galapagos NV (GLPG) Q1 2023 Earnings Conference Call May 05, 2023, 08:00 ET Company Participants Sofie Van Gijsel - Head, IR Paulus Stoffels - CEO, Chairman, Interim Head, R&D Bart Filius - President, COO & CFO Michele Manto - C...

P rogress with i mmunology and oncology pipeline : First patients dosed in pivotal Phase 3 OLINGUITO study with filgotinib in axial spondyloarthritis ( AxSpA ) Clinical sites opened to start patient recruitment in Pha...

Mechelen, Belgium; 2 May 2023, 22:01 CET ; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced the departure of Bart Filius , President, Chief Operating Officer and Chief Financial Officer . ...

OLINGUITO Phase 3 program in adults with axial spondyloarthritis (AxSpA) to include two parallel studies to investigate the efficacy and safety of filgotinib in patients with active radiographic AxSpA (r-AxSpA) and non-radiographic AxSpA (nr-AxSpA) Results from Phase 2 TORTUGA study showed th...

Mechelen, Belgium; 2 5 April 2023 , 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announces the approval of all resolutions proposed at its annual shareholders’ meeting (AGM) held today at 14.00 CET. The AGM appr...

Galapagos to transfer drug discovery and research activities in Romainville, France to NovAliX, a drug-discovery focused Contract Research Organization (CRO) based in Strasbourg, France NovAliX to assume Galapagos’ research capabilities, and Galapagos retains flexibility to access nece...

Publication of annual report for financial year 2022 Annual S hareholders ’ M eeting proposed resolutions include re - appointment of Board members and appointment of new statutory a uditor ...

Mechelen, Belgium; 20 March 202 3 , 2 1 .01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises . Galapagos issued 61,560 new ordinary shar...

2023-03-05 22:12:31 ET Summary David Einhorn's 13F stock portfolio value increased from $1.41B to $1.44B this quarter. Greenlight added Tenet Healthcare and increased Kyndryl Holdings, Southwestern Energy, and Global Payments during the quarter. The largest three positions are...

Six presentations demonstrate Galapagos’ commitment to the inflammatory bowel disease (IBD) community New analyses from Phase 3 SELECTION and SELECTION long-term extension (LTE) studies of Jyseleca ® (filgotinib, an oral, once daily, JAK1 preferential inhibitor) will be pres...